2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2907

The Natural History of Thrombotic Events in Systemic Lupus Erythematosus and Associated Risk Factors
Abstract Number: 2

The Neutrophil Protein S100A12 Has Stronger Associations with a Comprehensive Ultrasound Score of Synovitis Than Vascular Endothelial Growth Factor in a Longitudinal Study of Rheumatoid Arthritis Patients
Abstract Number: 6

The Novel Role of Corticotropin-Releasing Hormone and Urocortin1 on Sjogren’s Syndrome
Abstract Number: 2568

The Osteoimmunological Mechanistic Basis of Low-Dose Radiotherapy in TNF Driven Arthritis
Abstract Number: 1756

The Oxidative Burst Mediates Anti-Inflammatory Clearance of Dead Cells in a Mouse Model of SLE and Inflammatory Arthritis
Abstract Number: 2692

The Patients Evaluation of Pain and Disease Activity As Well As Improvement during One-Year Follow-up on Etanercept Treatment Is Highly Associated to Subjective Factors and Not to Objective Assessments Including Ultrasound
Abstract Number: 1291

The Pediatric Rheumatology Workforce in 2015: A Survey of Pediatric Rheumatologists
Abstract Number: 1955

The Performance of Colour-Doppler Sonography of Temporal Arteries in Patients Suspect of Having Giant Cell Arteritis in Daily Clinical Practice
Abstract Number: 652

The Performance of Different Classification Criteria Sets for Spondyloarthritis in the Worldwide ASAS-Comospa Study
Abstract Number: 1344

The Positive Synovial Fluid Culture: Septic Arthritis or Contamination?
Abstract Number: 1079

The Potential Effect on Recruitment of Restricting Skin Scores Eligibility Criteria in Early Diffuse Scleroderma Trials
Abstract Number: 2281

The Prediction of Fatigue in Early Rheumatoid Arthritis Patients
Abstract Number: 651

The Prediction of Long-Term Minimal Disease Activity and Its Benefits in Patients with Psoriatic Arthritis
Abstract Number: 3253

The Predictive Value of Antibodies to Cyclic Citrullinated Peptide in Two Prospective Early Rheumatoid Arthritis Cohorts 10 Years Apart
Abstract Number: 1882

The Predictive Value of Pulmonary Function Tests to Diagnose Interstitial Lung Disease in Adults with Early Diffuse Cutaneous Systemic Sclerosis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].